Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the International Antiviral Society–USA Panel
MS Saag, CA Benson, RT Gandhi, JF Hoy… - Jama, 2018 - jamanetwork.com
Importance Antiretroviral therapy (ART) is the cornerstone of prevention and management of
HIV infection. Objective To evaluate new data and treatments and incorporate this …
HIV infection. Objective To evaluate new data and treatments and incorporate this …
A review of long-term toxicity of antiretroviral treatment regimens and implications for an aging population
A Chawla, C Wang, C Patton, M Murray… - Infectious diseases and …, 2018 - Springer
Human immunodeficiency virus (HIV) is a chronic infectious disease currently requiring
lifelong antiretroviral therapy (ART). People living with HIV (PLWH) face an increased risk of …
lifelong antiretroviral therapy (ART). People living with HIV (PLWH) face an increased risk of …
HIV treatment with the two-drug regimen dolutegravir plus lamivudine in real-world clinical practice: a systematic literature review
R Patel, L Evitt, I Mariolis, S Di Giambenedetto… - Infectious Diseases and …, 2021 - Springer
The two-drug regimen dolutegravir plus lamivudine demonstrated durable efficacy for up to
3 years in phase III studies and a high barrier to resistance in treatment-naive and …
3 years in phase III studies and a high barrier to resistance in treatment-naive and …
Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority …
Background Lifelong HIV antiretroviral therapy (ART) has prompted an interest in two-drug
regimens to minimise cumulative drug exposure and toxicities. The safety, tolerability, and …
regimens to minimise cumulative drug exposure and toxicities. The safety, tolerability, and …
Durable efficacy of dolutegravir plus lamivudine in antiretroviral treatment–naive adults with HIV-1 infection: 96-week results from the GEMINI-1 and GEMINI-2 …
Background: The 2-drug regimen dolutegravir+ lamivudine was noninferior to dolutegravir+
tenofovir disoproxil fumarate/emtricitabine in achieving HIV-1 RNA< 50 copies/mL in …
tenofovir disoproxil fumarate/emtricitabine in achieving HIV-1 RNA< 50 copies/mL in …
A 4-days-on and 3-days-off maintenance treatment strategy for adults with HIV-1 (ANRS 170 QUATUOR): a randomised, open-label, multicentre, parallel, non …
Background Intermittent (on 4 days per week) antiretroviral therapy (ART) for patients with
HIV-1 might be more convenient, better tolerated, and cheaper than continuous treatment …
HIV-1 might be more convenient, better tolerated, and cheaper than continuous treatment …
Dolutegravir plus lamivudine maintains human immunodeficiency virus-1 suppression through week 48 in a pilot randomized trial
BO Taiwo, VC Marconi, B Berzins… - Clinical Infectious …, 2018 - academic.oup.com
In this randomized pilot clinical trial, dolutegravir plus lamivudine was noninferior to
continuation of standard 3-drug maintenance antiretroviral therapy. There was no …
continuation of standard 3-drug maintenance antiretroviral therapy. There was no …
Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat …
Background Simplified regimens with reduced pill burden and fewer side-effects are
desirable for people living with HIV. We investigated the efficacy and safety of switching to a …
desirable for people living with HIV. We investigated the efficacy and safety of switching to a …
Dual therapy with darunavir and ritonavir plus lamivudine vs triple therapy with darunavir and ritonavir plus tenofovir disoproxil fumarate and emtricitabine or abacavir …
F Pulido, E Ribera, M Lagarde… - Clinical Infectious …, 2017 - academic.oup.com
Background Our objective was to assess the therapeutic noninferiority of dual therapy with
darunavir/ritonavir and lamivudine compared to triple therapy with darunavir/ritonavir plus 2 …
darunavir/ritonavir and lamivudine compared to triple therapy with darunavir/ritonavir plus 2 …
Two‐drug vs. three‐drug combinations for HIV‐1: Do we have enough data to make the switch?
Three‐drug combination antiretroviral therapy (ART) became available in 1996, dramatically
improving the prognosis of people living with HIV. The clinical benefits of ART are due to the …
improving the prognosis of people living with HIV. The clinical benefits of ART are due to the …